Earnings Beat: Innovent Biologics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

It's been a good week for Innovent Biologics, Inc. (HKG:1801) shareholders, because the company has just released its latest half-yearly results, and the shares gained 6.3% to HK$108. Revenues missed the mark, coming in 12% below forecasts, at CN¥8.6b. Statutory profits were a real bright spot in contrast, with per-share profits of CN¥0.70 being a notable 49% above what the analysts were modelling. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

After the latest results, the 29 analysts covering Innovent Biologics are now predicting revenues of CN¥18.6b in 2026. If met, this would reflect a notable 19% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 79% to CN¥1.27. In the lead-up to this report, the analysts had been modelling revenues of CN¥18.4b and earnings per share (EPS) of CN¥1.16 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

See our latest analysis for Innovent Biologics

The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 6.8% to HK$128. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Innovent Biologics analyst has a price target of HK$150 per share, while the most pessimistic values it at HK$94.09. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Innovent Biologics' past performance and to peers in the same industry. The analysts are definitely expecting Innovent Biologics' growth to accelerate, with the forecast 40% annualised growth to the end of 2026 ranking favourably alongside historical growth of 29% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 21% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Innovent Biologics is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Innovent Biologics following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Innovent Biologics going out to 2028, and you can see them free on our platform here..

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.